Tricia Blankenbiller

Statistics

Publications

Citations

1.4K

H-Index

Active since

2017

Affiliations

Teva Pharmaceuticals (United States)(Current)

Thomas Jefferson University

Mayo Clinic Hospital

King's College London

Tricia Blankenbiller is an author at Teva Pharmaceuticals (United States) specializing in calcitonin gene-related peptide monoclonal antibodies, headache disorders, and headache assessment.

Publications per year

2017–2019

Publications

Fremanezumab for the Preventive Treatment of Chronic Migraine

Stephen D. Silberstein, David W. Dodick, Marcelo E. Bigal et al. · New England Journal of Medicine · 2017 · 803 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

David W. Dodick, Stephen D. Silberstein, Marcelo E. Bigal et al. · JAMA · 2018 · 573 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine

Paul Winner, Egilius L.H. Spierings, Paul Yeung et al. · Headache The Journal of Head and Face Pain · 2019 · 46 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine

Jan Lewis Brandes, David Kudrow, Paul Yeung et al. · Cephalalgia · 2019 · 24 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

1–4 of 4